facing lawsuits related to patient injuries caused by its vaginal mesh products. The issue is not unique to Endo--competitors CR Bard , Boston Scientific, Johnson & Johnson, and others are facing litigation for similar products--but it could face a significant
By Paul Franke : Since we are in the middle of football season, let's review some football words of wisdom and translate them into successful stock market investing suggestions. "Defense wins championships!" was an idea popularized by University of Alabama 's famous football coach, Paul BEAR ...
S.A.'s (BRD) and Banca Comerciala Romana S.A.'s ( BCR ) Long-term Issuer Default Ratings (IDR) at 'BBB+' and ..... The Outlooks are Stable. The agency has also downgraded BCR 's Viability Rating (VR) to 'b+' from 'bb-'. A full
substantial market share decline for Bard. C . R . Bard 's line of infection-control products ..... when capital spending is low. We rate C . R . Bard 's stewardship as Standard. Chairman ..... lower executive compensation rates than C . R . Bard . We also would like to see more disclosure
PR ) FY13 outlook: EPS of $0.58-0.60 on sales of $139-141M. $0.29/share is attributable to CRY's investment in Medafor, which C . R . Bard recently acquired. See: CRY makes nice profit on Medafor stake Post your comment!
CR Bard posted strong third-quarter results that slightly exceeded our expectations. We plan to modestly raise our fair value estimate
increased its litigation reserve to $216 million to account for the increase, but based on recent settlements of similar cases against competitors such as C . R . Bard , it wouldn't be surprising to see the final expense exceed that amount.
(Reuters) - Medical device company C . R . Bard Inc said it would buy Rochester Medical Inc, which makes products for urinary retention and incontinence, for about $262 million to boost its presence in...
By Stephen Simpson, CFA : I've had a love/hate relationship with Spectranetics ( SPNC ) for more than 15 years now. I've always loved the potential of the company's laser ablation products in markets like pacemaker/ICD lead removal and peripheral atherectomy, but I've hated the company's pattern of
We found few surprises in C . R . Bard 's BCR underlying business in the second quarter, and we are standing behind our $107 fair value estimate. The firm remains on track